Peptide stacks · Healing and repair
KLOW peptide blend: what’s in it and the evidence
Checked against our library and study pagesPublished by PepVault
KLOW is a blend of four compounds, KPV, BPC-157, TB-500 and GHK-Cu, that the peptide community runs for repair and recovery. The vial the library records holds 80 mg of powder in all: 50 mg of GHK-Cu and 10 mg each of KPV, BPC-157 and TB-500.
This page describes what the crowd runs and what a vial holds. It recommends no stack and names no seller.
What’s in KLOW
| Part | Amount | What it’s there for | Evidence (library) |
|---|---|---|---|
| KPV | 10 mg in the vial; 250 mcg per dose reported | Lys-Pro-Val — calms inflammatory signaling, gut focus | Emerging |
| BPC-157 | 10 mg in the vial; 250 mcg per dose reported | Body Protection Compound 157 — new blood vessels, tendon & gut repair | Emerging |
| TB-500 | 10 mg in the vial; 250 mcg per dose reported | Thymosin beta-4 fragment — cell migration & wound repair | Emerging |
| GHK-Cu | 50 mg in the vial; 1.25 mg per dose reported | Copper peptide — collagen & skin remodeling | Emerging |
What the 80 mg vial holds, part by part
KPV
In KLOW, KPV is listed for “Lys-Pro-Val — calms inflammatory signaling, gut focus”. One of the smallest bioactive peptides: three amino acids from the tail end of α-MSH.
BPC-157
In KLOW, BPC-157 is listed for “Body Protection Compound 157 — new blood vessels, tendon & gut repair”. A peptide derived from a protective protein in the stomach.
TB-500
In KLOW, TB-500 is listed for “Thymosin beta-4 fragment — cell migration & wound repair”. A fragment of thymosin beta-4, a protein the body uses for cell repair.
GHK-Cu
In KLOW, GHK-Cu is listed for “Copper peptide — collagen & skin remodeling”. A small copper-binding peptide found naturally in the blood and widely used in skincare.

Has KLOW been studied as a combination?
1 study page of ours tested KPV, BPC-157, TB-500 and GHK-Cu together:
What the library says about the evidence for KLOW
The research behind each peptide is mostly cell and animal work, and the four haven't been formally studied together. No study has tested the safety of these four peptides together, so each compound's own notes apply and add up. No study has combined all four; the one combination test, BPC-157 with TB-500 in rats, found no added benefit (Biçer 2026).
The studies of the parts, one by one: 3 study pages on KPV (0 in people), 14 study pages on BPC-157 (2 in people), 9 study pages on TB-500 (2 in people) and 11 study pages on GHK-Cu (2 in people).
What people commonly report on KLOW
Commonly reported: a calmer gut, and faster tendon and skin recovery. A calmer gut within a few weeks, then nagging tendon pain easing and better skin.
These are reports from people who run it, collected in the library, not results from a trial and not a promise of what any one person will notice.
Why these are combined
The library gives four reasons for combining the parts of KLOW:
- KLOW is built to cover the whole arc of repair: KPV calms inflammation, BPC-157 rebuilds blood supply, TB-500 moves repair cells in, and GHK-Cu boosts collagen. Each role comes from its own research, mostly in animals.
- In KLOW, KPV is the inflammation brake: it damped NF-κB, a main switch for inflammatory signals, in human cells and eased colitis in mice. Calming excess inflammation clears the way for the other three.
- In KLOW, GHK-Cu brings copper, which lysyl oxidase, the enzyme that cross-links collagen into strong fibers, needs to work, so tissue rebuilt with BPC-157 and TB-500 matures stronger.
- KLOW's gut angle: KPV and BPC-157 were each studied on the gut from a different side, KPV on inflammation in mice and BPC-157 on healing in rats. That pairing is why KLOW is popular for gut goals.
From the library’s notes on KLOW
KLOW is GLOW with KPV added. It is a community formula, not a product that has been through trials.
“Four peptides, one injection: keep the basics tight”, the library’s note on the four (community report)
KLOW puts four peptides in every injection, each with its own side-effect profile, so the basics count for more: rotate sites, keep every vial clean, and log anything new.
“KLOW is four jobs in one repair arc”, the library’s note on the four (community report)
KLOW is designed to cover the whole arc of repair: KPV calms the inflammation, BPC-157 builds new blood supply, TB-500 moves repair cells in, and GHK-Cu lays down collagen. KPV blocked NF-κB signaling in human intestinal and airway cells, apparently from inside the cell rather than through melanocortin receptors (Dalmasso 2008; Getting 2003; Land 2012). BPC-157 raised VEGFR2 and vessel growth in ischemic rat limbs (Hsieh 2017). TB-500 is Ac-LKKTETQ, the 7-amino-acid actin-binding piece of thymosin beta-4, a protein that binds actin monomers and holds them back from polymerizing (Esposito 2012; Safer 1991). GHK-Cu raised collagen and decorin in rat wound chambers (Maquart 1993; Siméon 2000).
The library’s note on the four (community report)
By months two and three of a repair block, most healing is in its remodeling stage: collagen keeps cross-linking and tissue keeps reorganizing even as day-to-day changes slow. A 2025 review (McGuire et al.) finds only three small pilot studies of BPC-157 in people and no rigorous large-scale trial. FDA (April 2026) has found no human exposure data at all for TB-500 or KPV, and only limited human data for injected GHK-Cu. The combined proangiogenic load of BPC-157 and TB-500 is most worth discussing for open-ended continuous use. There is no evidence-based endpoint for a KLOW block.
The library’s notes on the smaller stacks inside KLOW, each on its own page:
- “BPC-157 + TB-500 hit two different arms of healing” (Wolverine stack)
- “GHK-Cu + BPC-157: skin on top, structure underneath” (BPC-157 and GHK-Cu stack)
- “Why KPV + BPC-157 is the gut pairing” (KPV and BPC-157 stack)
- “GHK-Cu + TB-500: skin plus recovery” (GLOW peptide blend)
- “BPC-157 + TB-500 + GHK-Cu is the classic healing trio” (GLOW peptide blend)
- “GLOW aims skin-deep and structure-deep at once” (GLOW peptide blend)
- “The classic healing combo” (Wolverine stack)
- “Why GHK-Cu pairs with healing peptides” (GLOW peptide blend)
- “Why KPV pairs with BPC-157 for gut” (KPV and BPC-157 stack)
How a KLOW vial is mixed and measured
The vial the library records for KLOW holds 80 mg of powder, mixed with 2 mL of bacteriostatic water. Every part dissolves into the same water, so each mL holds 25 mg of GHK-Cu, 5 mg of KPV, 5 mg of BPC-157 and 5 mg of TB-500.
| Part | In the vial | Share | Per mL | In 10 units (0.1 mL) |
|---|---|---|---|---|
| GHK-Cu | 50 mg | 62.5% | 25 mg | 2.5 mg |
| KPV | 10 mg | 12.5% | 5 mg | 500 mcg |
| BPC-157 | 10 mg | 12.5% | 5 mg | 500 mcg |
| TB-500 | 10 mg | 12.5% | 5 mg | 500 mcg |
One draw carries every part at the vial’s ratio. The 250 mcg of KPV that KLOW’s entry lists is 5 units (0.05 mL) on a U-100 syringe, and that same draw holds 1.25 mg of GHK-Cu, 250 mcg of BPC-157 and 250 mcg of TB-500.
The ratio is fixed at 5 to 1 to 1 to 1 (GHK-Cu, KPV, BPC-157 and TB-500), so a draw that holds more of one part holds more of all of them; a pre-mixed vial can’t change one part on its own.
The arithmetic only divides what the vial holds by the water it is mixed with; it says nothing about what amount anyone should take.
Compared with running the parts apart
What the library says about KLOW against its parts on their own:
- All four share one pre-mixed vial at a fixed ratio (50 mg GHK-Cu to 10 mg each of the others), so a single draw sets every dose.
- KPV is also taken orally on its own.
Safety notes
The library’s combination safety note on KLOW
FDA (April 2026) says it has found no human exposure data for TB-500 or KPV and little or no safety data for BPC-157 and injectable GHK-Cu; it also flags a possible risk of immune reactions to compounded BPC-157, TB-500 and injectable GHK-Cu. Two threads are worth a clinician conversation: BPC-157 and TB-500 both promote new blood vessel growth in lab and animal studies, a theoretical concern with any existing or undiagnosed cancer, and GHK-Cu carries copper, relevant to copper-metabolism disorders such as Wilson's disease. Injection-site reactions are the most common effect in community reports.
From the library’s notes on the combination
Worth being honest about the evidence: none of KLOW's four peptides has controlled long-term safety data in people.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Questions people ask
What is in KLOW?
KLOW is a blend of four compounds, KPV, BPC-157, TB-500 and GHK-Cu, that the peptide community runs for repair and recovery. The vial the library records holds 80 mg of powder in all: 50 mg of GHK-Cu and 10 mg each of KPV, BPC-157 and TB-500.
Has KLOW been studied together?
Yes: 1 study page of ours tested KPV, BPC-157, TB-500 and GHK-Cu together, starting with “BPC-157: non-significant tendon gains in rats; TB-500 did better”.
What do people report on KLOW?
Commonly reported: a calmer gut, and faster tendon and skin recovery. These are reports from people who run it.
How is a KLOW vial measured?
The vial the library records holds 80 mg with 2 mL of water, at a fixed ratio, so one draw carries every part; the reconstitution calculator works out the units for a vial.
What does each part of KLOW do?
The library lists KPV for “Lys-Pro-Val — calms inflammatory signaling, gut focus”, BPC-157 for “Body Protection Compound 157 — new blood vessels, tendon & gut repair”, TB-500 for “Thymosin beta-4 fragment — cell migration & wound repair” and GHK-Cu for “Copper peptide — collagen & skin remodeling”.
How does KLOW compare with taking the parts separately?
From the library: All four share one pre-mixed vial at a fixed ratio (50 mg GHK-Cu to 10 mg each of the others), so a single draw sets every dose.